Top

International Journal of Clinical Oncology

Published in:

01-04-2020 | Hyponatremia | Original Article

Prognostic significance of hyponatremia induced by systemic chemotherapy in a hospital-based propensity score-matched analysis

Authors: Yosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, Yuki Kondo, Tomoya Kataoka, Toshiki Etani, Keitaro Iida, Satoshi Nozaki, Ryosuke Ando, Satoshi Osaga, Takahiro Yasui, Kazunori Kimura

Published in: International Journal of Clinical Oncology | Issue 4/2020

Abstract

Background

During chemotherapy, hyponatremia is one of the most frequently encountered adverse effects. This study aimed to investigate the prognostic impact of hyponatremia induced by systemic chemotherapy (HIC) using a propensity matching method in cumulative pooled data.

Methods

Between January 2011 and July 2017, 2129 patients were administered systemic chemotherapy for malignancy in various organs at Nagoya City University Hospital. Patients were divided into two groups: a grade 0–1 group (control group) and a grade 3–4 group (severe group) according to the severity of HIC appearing within 30 days after starting treatment. Kaplan–Meier curves were used for survival and recurrence analyses using a propensity case-matched analysis.

Result

The number of severe HIC patients was 93 (4.4%). In platinum-containing regimens, HIC appeared at higher frequencies. In the 21.2 months median follow-up period, the median OS (mOS) in the severe group was 49.1 months, which was significantly worse than the mOS in the control group; the OS in the control group did not reach the median. Univariate and multivariate analyses of associated factors in patients with grade 3–4 HIC revealed that renal dysfunction, cisplatin-containing regimen, and infusion of more than 5000 mL fluid was associated with HIC.

Conclusion

This study suggests that severe HIC in the first treatment cycle affects survival time. Chemotherapy patients receiving extensive hydration should be required to undergo frequent monitoring of serum sodium levels, especially patients receiving platinum-containing regimens.

Hori M, Matsuda T, Shibata C et al (2009) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015(45):884–891

Thompson C, Hoorn EJ (2012) Hyponatraemia: an overview of frequency, clinical presentation and complications. Best Pract Res Clin Endocrinol Metab 26(Suppl 1):S1–6CrossRef

Adrogue HJ, Madias NE (2000) Hyponatremia. N Engl J Med. 342:1581–1589CrossRef

Spasovski G, Vanholder R, Allolio B et al (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med 40:320–331CrossRef

Yokoyama Y, Shigeto T, Futagami M et al (2005) Syndrome of inappropriate secretion of anti-diuretic hormone following carboplatin-paclitaxel administration in a patient with recurrent ovarian cancer. Eur J Gynaecol Oncol 26:531–532PubMed

Sterns RH (2015) Disorders of plasma sodium–causes, consequences, and correction. N Engl J Med 372:55–65CrossRef

Sugiyama Y, Naiki T, Kondo M et al (2017) Syndrome of inappropriate secretion of antidiuretic hormone caused by carboplatin after switching from cisplatin in a metastatic urethral cancer patient. Urol Case Rep 12:17–19CrossRef

Dhaliwal HS, Rohatiner AZ, Gregory W et al (1993) Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 68:767–774CrossRef

Tokunaga K, Matsuzawa Y, Kotani K et al (1991) Ideal body weight estimated from the body mass index with the lowest morbidity. Int J Obes 15:1–5PubMed

10.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

11.

Shrotriya S, Walsh D, Bennani-Baiti N et al (2015) C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS O ne 10:e0143080CrossRef

12.

Bacha S, Sghaier A, Habibech S et al (2017) Combined C-reactive protein and neutrophil to lymphocyte ratio use predict survival innon-small-cell lung cancer. Tunis Med 95:229–235PubMed

13.

Wang Y, Yang L, Xia L et al (2018) High C-reactive protein/albumin ratio predicts unfavorable distant metastasis-free survival in nasopharyngeal carcinoma: a propensity score-matched analysis. Cancer Manag Res 10:371–381CrossRef

14.

Chen Y, Wang Y, Shi Y et al (2017) Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6-treated patients. BMC Cancer 17:242CrossRef

15.

Berghmans T, Paesmans M, Body JJ (2000) A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 8:192–197CrossRef

16.

Rodrigues B, Staff I, Fortunato G et al (2014) Hyponatremia in the prognosis of acute ischemic stroke. J Stroke Cerebrovasc Dis 23:850–854CrossRef

17.

Huang WY, Weng WC, Peng TI et al (2012) Association of hyponatremia in acute stroke stage with three-year mortality in patients with first-ever ischemic stroke. Cerebrovasc Dis 34:55–62CrossRef

18.

Furukawa J, Miyake H, Kusuda Y et al (2015) Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor. Int J Clin Oncol 20:351–357CrossRef

19.

Funk GC, Lindner G, Druml W et al (2010) Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med 36:304–311CrossRef

20.

Ko SK, Kim SK, Share A et al (2014) Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells. Nat Chem 6:885–892CrossRef

21.

Hayes DM, Cvitkovic E, Golbey RB et al (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381CrossRef

22.

Kubala M, Geleticova J, Huliciak M et al (2014) Na(+)/K(+)-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:194–200CrossRef

23.

Washam JB, Stevens SR, Lokhnygina Y et al (2015) Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 385:2363–2370CrossRef

24.

Oronsky B, Caroen S, Oronsky A et al (2017) Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol 80:895–907CrossRef

25.

Horinouchi H, Kubota K, Itani H et al (2013) Short hydration in chemotherapy containing cisplatin (≥ 75 mg/m²) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43:1105–1109CrossRef

26.

Horinouchi H, Kubota K, Miyanaga A et al (2018) Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. ESMO Open 3:e000288CrossRef

27.

Berger MJ, Ettinger DS, Aston J et al (2017) NCCN guidelines insights: antiemesis, Version 2.2017. J Natl Compr Canc Netw 15:883–893

28.

Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308CrossRef

29.

Goldvaser H, Rozen-Zvi B, Yerushalmi R et al (2016) Malignancy associated SIADH: characterization and clinical implications. Acta Oncol 55:1190–1195CrossRef

Title: Prognostic significance of hyponatremia induced by systemic chemotherapy in a hospital-based propensity score-matched analysis
Authors: Yosuke Sugiyama
Taku Naiki
Yoshihiko Tasaki
Yuki Kondo
Tomoya Kataoka
Toshiki Etani
Keitaro Iida
Satoshi Nozaki
Ryosuke Ando
Satoshi Osaga
Takahiro Yasui
Kazunori Kimura
Publication date: 01-04-2020
Publisher: Springer Singapore
Keywords: Hyponatremia
Syndrome of Inappropriate ADH Secretion
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01579-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

The impact of postoperative inflammation on recurrence in patients with colorectal cancer

Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma

Lack of association between interleukin-22 gene polymorphisms and cancer risk: a case–control study and a meta-analysis

LINC00163 inhibits the invasion and metastasis of gastric cancer cells as a ceRNA by sponging miR-183 to regulate the expression of AKAP12

Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer